Neurobo Pharmaceuticals Stock Fundamentals
| NRBO Stock | USD 3.44 0.02 0.58% |
Neurobo Pharmaceuticals fundamentals help investors to digest information that contributes to Neurobo Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Neurobo Stock. The fundamental analysis module provides a way to measure Neurobo Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neurobo Pharmaceuticals stock.
At this time, Neurobo Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 19th of April 2024, Other Operating Expenses is likely to grow to about 18.8 M, while Depreciation And Amortization is likely to drop 6,650. Neurobo | Select Account or Indicator |
Neurobo Pharmaceuticals Company Return On Equity Analysis
Neurobo Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Neurobo Pharmaceuticals Return On Equity | -0.65 |
Most of Neurobo Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neurobo Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Neurobo Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Neurobo Pharmaceuticals has a Return On Equity of -0.6489. This is 97.29% lower than that of the Biotechnology sector and 98.22% lower than that of the Health Care industry. The return on equity for all United States stocks is 109.32% higher than that of the company.
Neurobo Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Neurobo Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Neurobo Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neurobo Pharmaceuticals competition to find correlations between indicators driving Neurobo Pharmaceuticals's intrinsic value. More Info.Neurobo Pharmaceuticals is regarded second in return on equity category among related companies. It is regarded third in return on asset category among related companies . At this time, Neurobo Pharmaceuticals' Return On Equity is very stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Neurobo Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Neurobo Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Neurobo Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Neurobo Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neurobo Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neurobo Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Neurobo Pharmaceuticals by comparing valuation metrics of similar companies.Neurobo Pharmaceuticals is currently under evaluation in return on equity category among related companies.
Neurobo Fundamentals
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.35 | ||||
| Current Valuation | (5.26 M) | ||||
| Shares Outstanding | 4.91 M | ||||
| Shares Owned By Insiders | 61.66 % | ||||
| Shares Owned By Institutions | 1.36 % | ||||
| Number Of Shares Shorted | 61.89 K | ||||
| Price To Earning | (1.44) X | ||||
| Price To Book | 1.06 X | ||||
| Revenue | 7 K | ||||
| EBITDA | (15.88 M) | ||||
| Net Income | (12.47 M) | ||||
| Cash And Equivalents | 8.85 M | ||||
| Cash Per Share | 9.96 X | ||||
| Total Debt | 203 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 8.07 X | ||||
| Book Value Per Share | 3.40 X | ||||
| Cash Flow From Operations | (10.8 M) | ||||
| Short Ratio | 0.25 X | ||||
| Earnings Per Share | (2.46) X | ||||
| Target Price | 36.5 | ||||
| Beta | -0.46 | ||||
| Market Capitalization | 16.97 M | ||||
| Total Asset | 22.78 M | ||||
| Retained Earnings | (108.27 M) | ||||
| Working Capital | 16.55 M | ||||
| Current Asset | 21.62 M | ||||
| Current Liabilities | 11.75 M | ||||
| Net Asset | 22.78 M |
About Neurobo Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neurobo Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurobo Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurobo Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -2.2 M | -2.1 M | |
| Total Revenue | 7 K | 7.3 K | |
| Cost Of Revenue | 7 K | 6.7 K | |
| Stock Based Compensation To Revenue | 28.54 | 25.37 | |
| Sales General And Administrative To Revenue | 865.03 | 768.91 | |
| Research And Ddevelopement To Revenue | 1.2 K | 1 K | |
| Capex To Revenue | (6.43) | (6.75) | |
| Revenue Per Share | 0 | 0 | |
| Ebit Per Revenue | -2 K | -2.1 K |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Neurobo Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Neurobo Pharmaceuticals' short interest history, or implied volatility extrapolated from Neurobo Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Neurobo Pharmaceuticals Piotroski F Score and Neurobo Pharmaceuticals Altman Z Score analysis. To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.Note that the Neurobo Pharmaceuticals information on this page should be used as a complementary analysis to other Neurobo Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Neurobo Stock analysis
When running Neurobo Pharmaceuticals' price analysis, check to measure Neurobo Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurobo Pharmaceuticals is operating at the current time. Most of Neurobo Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Neurobo Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurobo Pharmaceuticals' price. Additionally, you may evaluate how the addition of Neurobo Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
Is Neurobo Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurobo Pharmaceuticals. If investors know Neurobo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurobo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.46) | Return On Assets (0.35) | Return On Equity (0.65) |
The market value of Neurobo Pharmaceuticals is measured differently than its book value, which is the value of Neurobo that is recorded on the company's balance sheet. Investors also form their own opinion of Neurobo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Neurobo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurobo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Neurobo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurobo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurobo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurobo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.